-
-
-
-
FDA Approves Repotrectinib (Augtyro) for NTRK
FDA
The FDA granted accelerated approval to repotrectinib (Augtyro) for adults and children aged 12+ with NTRK fusion-positive tumors. The TRIDENT-1 trial showed a 58% ORR in TKI-na?ve patients and a 50% ORR in TKI-pretreated patients, highlighting its efficacy and potential.
-
FDA Approves Imetelstat for Low- to Intermediate-1 Risk MDS
FDA
On June 6, 2024, the FDA approved imetelstat (Rytelo) for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) and transfusion-dependent anemia. The approval is based on significant trial results demonstrating RBC transfusion independence.
-
-
-
-
-
页游|
多伦县|
靖西县|
兰考县|
孟津县|
涿州市|
雷波县|
丹阳市|
镇安县|
云梦县|
新闻|
连平县|
龙井市|
泸水县|
政和县|
柞水县|
清流县|
桑日县|
辽源市|
寿光市|
聂拉木县|
农安县|
鹤峰县|
砚山县|
环江|
太仆寺旗|
五指山市|
安国市|
黑龙江省|
赣州市|
永州市|
安多县|
秦安县|
元朗区|
嘉兴市|
洪湖市|
益阳市|
陆河县|
双牌县|
唐河县|
湘乡市|